Reviewed by Michael Gill, B. Sc.
16 Paraganglioma Clinical Trials Near Me
Top Hospitals for Paraganglioma Clinical Trials
Image of National Institutes of Health Clinical Center in Maryland.
National Institutes of Health Clinical Center
Bethesda
3Active Trials
6All Time Trials for Paraganglioma
2012First Paraganglioma Trial
Image of Memorial Sloan Kettering Cancer Center in New York.
Memorial Sloan Kettering Cancer Center
New York
2Active Trials
1All Time Trials for Paraganglioma
2006First Paraganglioma Trial
Top Cities for Paraganglioma Clinical Trials
Image of New York in New York.
New York
8Active Trials
Memorial Sloan Kettering Cancer CenterTop Active Site
Image of Anchorage in Alaska.
Anchorage
8Active Trials
Anchorage Associates in Radiation MedicineTop Active Site
Paraganglioma Clinical Trials by Phase of Trial
Most Recent Paraganglioma Clinical Trials
Top Treatments for Paraganglioma Clinical Trials
Treatment Name
Active Paraganglioma Clinical Trials
All Time Trials for Paraganglioma
First Recorded Paraganglioma Trial
Talazoparib
1
1
2022
Belzutifan
1
1
2021
Lutetium [177Lu] oxodotreotide/dotatate
1
1
2022
Temozolomide
1
2
2020
177Lu-DOTATOC
1
1
2021
Recently Completed Studies with FDA Approved Treatments for Paraganglioma
Treatment
Year
Sponsor
Lenvatinib
2017
Mayo Clinic

What Are Paraganglioma Clinical Trials?

Paraganglioma is a form of neuroendocrine tumor. The formation of this tumor is on the patient's adrenal glands' outer nerves and blood vessels. These glands make hormones that are responsible for controlling several body functions. Paraganglioma is also known as extra-adrenal pheochromocytomas. The condition is progressive, and nearly 35 to 50 percent of paragangliomas spread to other body parts. Some people may experience symptoms while others may not. Symptoms of paraganglioma include:

  • A fast heartbeat
  • Headaches
  • Sweating
  • High blood pressure
  • Tremors

Paraganglioma clinical trials are studies conducted to find novel treatments and their efficacy. They help discover the best ways to identify, screen, and treat the condition.

Why Is Paraganglioma Being Studied Through Clinical Trials?

Paraganglioma is a rare condition affecting two out of every one million people. Though most common in adults aged 30 to 50, paraganglioma can also occur in children. Nearly 10 percent of paraganglioma cases in the US occur in young children.

Hence, paraganglioma clinical trials are necessary to develop quality health outcomes for those with the condition.

Furthermore, in most cases, the exact cause of paraganglioma is unknown. It can occur randomly. However, only 25 percent of the cases were associated with hereditary conditions like VHL, MEN2A or MEN2B, and NF1.

Therefore, paraganglioma clinical trials are crucial to gain more insights into paraganglioma and finding the underlying causes, prevention techniques, and cures for improving the patients' quality of life.  

What Are the Types of Treatments Available for Paraganglioma?

The treatment for paraganglioma is determined after taking into account multiple factors:

  • The tumor size
  • If it is benign or malignant
  • Its spread
  • If it is the first time it occurred or has recurred
  • The healthcare provider may recommend medication to control symptoms like alpha-blockers and beta-blockers. 

Treatments may include (separate or a combination of):

  • Surgery for tumor removal
  • Radiation
  • Ablation therapy
  • Chemotherapy
  • Targeted therapy

What Are Some Recent Breakthrough Clinical Trials for Paraganglioma?

2021: The use of immunotherapy treatment in malignant pheochromocytomas/paragangliomas: This report comprehensively details immunotherapy usage and its efficacy in managing paragangliomas. The case featured a 60-year-old woman with a malignant pheochromocytoma. Due to the critical location of the tumor, radiation therapy was not feasible. She started with immunotherapeutic agents. The therapy decreased tumor size while improving the quality of her life. The patient tolerated the treatment and exhibited progression-free survival.

2022: Treatment of Malignant Pheochromocytoma/Paraganglioma With Cyclophosphamide, Vincristine, and Dacarbazine-Eighteen patients with paraganglioma were treated using vincristine, cyclophosphamide, and dacarbazine. These medications were combined to create an effective treatment with chemotherapy. This combination produced impressive results with significant improvement in the patients' symptoms with paraganglioma.

Who Are Some of the Key Opinion Leaders/Researchers/Institutions Conducting Paraganglioma Clinical Trial Research?

Pheo Para Alliance

It is a non-profit organization dedicated to creating awareness of paraganglioma through advocacy and research. The organization has been serving the community for more than 15 years.

Dana Faber

The institute provides the best treatments to children and adults with cancer. It also performs research and clinical trials with a mission to discover cures with the highest level of efficacy and safety.

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 30th, 2021

Last Reviewed: November 8th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF Jr; Endocrine Society. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014 Jun;99(6):1915-42. doi: 10.1210/jc.2014-1498. https://pubmed.ncbi.nlm.nih.gov/248931352 Dai C, Liang S, Sun B, Kang J. The Progress of Immunotherapy in Refractory Pituitary Adenomas and Pituitary Carcinomas. Front Endocrinol (Lausanne). 2020 Dec 11;11:608422. doi: 10.3389/fendo.2020.608422. eCollection 2020. Review. https://pubmed.ncbi.nlm.nih.gov/333627223 Prys-Roberts C, Farndon JR. Efficacy and safety of doxazosin for perioperative management of patients with pheochromocytoma. World J Surg. 2002 Aug;26(8):1037-42. Epub 2002 Jun 19. https://pubmed.ncbi.nlm.nih.gov/121925334 Weingarten TN, Cata JP, O'Hara JF, Prybilla DJ, Pike TL, Thompson GB, Grant CS, Warner DO, Bravo E, Sprung J. Comparison of two preoperative medical management strategies for laparoscopic resection of pheochromocytoma. Urology. 2010 Aug;76(2):508.e6-11. doi: 10.1016/j.urology.2010.03.032. Epub 2010 May 23. https://pubmed.ncbi.nlm.nih.gov/205468745 Hahn AW, Chahoud J, Campbell MT, Karp DD, Wang J, Stephen B, Tu SM, Pettaway CA, Naing A. Pembrolizumab for advanced penile cancer: a case series from a phase II basket trial. Invest New Drugs. 2021 Oct;39(5):1405-1410. doi: 10.1007/s10637-021-01100-x. Epub 2021 Mar 26. https://pubmed.ncbi.nlm.nih.gov/337702916 Patel SP, Othus M, Chae YK, Giles FJ, Hansel DE, Singh PP, Fontaine A, Shah MH, Kasi A, Baghdadi TA, Matrana M, Gatalica Z, Korn WM, Hayward J, McLeod C, Chen HX, Sharon E, Mayerson E, Ryan CW, Plets M, Blanke CD, Kurzrock R. A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART SWOG 1609) in Patients with Nonpancreatic Neuroendocrine Tumors. Clin Cancer Res. 2020 May 15;26(10):2290-2296. doi: 10.1158/1078-0432.CCR-19-3356. Epub 2020 Jan 22. https://pubmed.ncbi.nlm.nih.gov/319693357 Frumovitz M, Westin SN, Salvo G, Zarifa A, Xu M, Yap TA, Rodon AJ, Karp DD, Abonofal A, Jazaeri AA, Naing A. Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract. Gynecol Oncol. 2020 Sep;158(3):570-575. doi: 10.1016/j.ygyno.2020.05.682. Epub 2020 Jun 11. https://pubmed.ncbi.nlm.nih.gov/325348098 Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 Mar;8(1). pii: e000347. doi: 10.1136/jitc-2019-000347. Erratum in: J Immunother Cancer. 2020 Apr;8(1):. https://pubmed.ncbi.nlm.nih.gov/321887049 Ferrarotto R, Sousa LG, Qing Y, Kaya D, Stephen B, Jain D, Bell D, Pant S, Tsimberidou AM, Janku F, Blumenschein G, Glisson BS, Ahnert JR, Piha-Paul SA, Lee JJ, Wong MK, Lu C, Meric-Bernstam F, Naing A. Pembrolizumab in Patients with Refractory Cutaneous Squamous Cell Carcinoma: A Phase II Trial. Adv Ther. 2021 Aug;38(8):4581-4591. doi: 10.1007/s12325-021-01807-6. Epub 2021 Jul 9. https://pubmed.ncbi.nlm.nih.gov/3424178110 Naing A, Meric-Bernstam F, Stephen B, Karp DD, Hajjar J, Rodon Ahnert J, Piha-Paul SA, Colen RR, Jimenez C, Raghav KP, Ferrarotto R, Tu SM, Campbell M, Wang L, Sabir SH, Tapia C, Bernatchez C, Frumovitz M, Tannir N, Ravi V, Khan S, Painter JM, Abonofal A, Gong J, Alshawa A, McQuinn LM, Xu M, Ahmed S, Subbiah V, Hong DS, Pant S, Yap TA, Tsimberidou AM, Dumbrava EEI, Janku F, Fu S, Simon RM, Hess KR, Varadhachary GR, Habra MA. Phase 2 study of pembrolizumab in patients with advanced rare cancers. J Immunother Cancer. 2020 Mar;8(1):e000347. doi: 10.1136/jitc-2019-000347. Erratum In: J Immunother Cancer. 2020 Apr;8(1): https://pubmed.ncbi.nlm.nih.gov/32188704